#PAMTASTIC 🤩🤩🤩

I'm excited & proud to share work from my DPhil Oxford Uni Students & an amazing collaboration with Anna Gloyn, Mark McCarthy, Elisa Araldi, PhD & Markus Stoffel. We show that variants in the #T2D risk gene PAM alter GLP-1 levels & response to GLP-1 receptor agonists medrxiv.org/content/10.110…

New from Anna Gloyn Human carriers of hypomorphic #T2D risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase (PAM) exhibit reduced glucose-lowering responses to Rxment with GLP-1R agonist, likely not related to #islet actions medrxiv.org/content/10.110…

On 9 May 6.30 pm at Italian Embassy Berlin event on “Research, engine of growth”, with Elisa Araldi, PhD, J. Mlynek (Falling Walls), and SIGN founding members @franceschini_ch, S. Pascarelli, R. Tamai, and Emilio Zagheni. Info and invites: [email protected]

Thread 1/4: Which #antidiabetic #drugs reduce #mortality in type 2 #diabetes? We have analysed 43,610 T2Ds from UK Biobank combined with prescription data from NHS by nearest neighbour covariate matching (NNCM) #T2D #T2DM Elisa Araldi, PhD Catherine Jutzeler-Walter buff.ly/3onEvOU

Thread 2/4: Comparing T2Ds taking a specific drug with T2Ds taking any other drug we observe that only metformin (HR 0.39, 95%CI 0.31 to 0.49) and SGLT2-inhibitors (HR 0.58, 95%CI 0.36 to 0.93) increase survival. #T2D #T2DM UK Biobank NHS Elisa Araldi, PhD buff.ly/3onEvOU

Thread 3/4: Comparing #T2Ds taking a specific #drug with otherwise matched #diabetes-free individuals, we observe that only #SGLT2-inhibitors (HR 0.31, 95%CI 0.19 to 0.51) increase #survival probability. #T2D #T2DM UK Biobank NHS Elisa Araldi, PhD buff.ly/3onEvOU

Thread 4/4: NNCM-matched individuals with T2D on both SGLT2I and metformin vs metformin reveals increased survival in the presence of SGLT2I (HR 0.29, 95%CI 0.09 to 0.91) only, also compared to persons without T2D (average hazard ratio 0.05, 95% confidence interval 0.01 to 0.19)

Re. thread & data above: #PDF and #preprint available at #medRxiv, #DOI & link doi.org/10.1101/2023.0… #aging #ageing #mortality #suvival #longevity #lifespan #healthspan #health #geroprotectors #geroprotector #human #TAME #pharma #pharmacology #biguanides #glifozin #gliflozins

🚨🚨🚨 my lab latest peer-reviewed paper is out Frontiers - Endocrinology 😃 Check it out for free @ tinyurl.com/28x299ru It reports the identification of PAM (peptidylglycine α-amidating monooxygenase) as a candidate gene associated with pituitary hormone hypersecretion. A 🧵 1/9

So proud to be part of this massive effort! Congratulations Giampaolo Trivellin and team!!!

📢 The Longevist Curators have spoken - The 2nd Edition of The Longevist is now live! 🎉 Our expert team of Curators voted on-chain 🗳️ to determine which preprints from Q2 2023 are set to impact the longevity field! 🧬 👉longevist.xyz 🧵

🥈 In 2nd Place: Effects of antidiabetic drugs on mortality risks in type 2 diabetes 🩺: A cohort study of UK Biobank participants - Elisa Araldi, PhD Michael Ristow, MD

Today Maximilian Nuber and Katrin presented their work at the young #DZHK retreat. It is cliché to say that I'm proud, but I don't care. I'm super proud of them and their work 😎

Read it here 🤓: medrxiv.org/content/10.110…

Joining Elisa Araldi, PhD lab. A new enthusiastic beginning. I propose a toast for those amazing things to come.

First official lunch of the Elisa Araldi, PhD lab!

📢#PhD position available in the CDC lab focused on modelling the effect of genetic variation on T cell development and function Human Technopole Applications open: semm.it/education/appl… Please, share! 🙏

🇪🇺 I have been awarded a European Research Council (ERC) Starting Grant #ERCStG to study how endogenous amidated hormones contribute to the effectiveness of the anti-diabetic drugs GLP-1RA (acronym GLP1RES). 🙏Very grateful to my colleagues and collaborators for their support.